XSTO
NOLA B
Market cap1.36bUSD
Jul 09, Last price
48.75SEK
1D
0.62%
1Q
-4.04%
Jan 2017
85.36%
Name
Nolato AB
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nolato AB (publ) is a company that develops, manufactures, and distributes products made from plastic, silicone, and thermoplastic elastomers. The company serves diverse global markets, including medical technology, pharmaceuticals, consumer electronics, telecommunications, automotive, and various other industrial sectors throughout North America, Sweden, Asia, and other European regions. Within the medical and pharmaceutical fields, Nolato provides both disposable and reusable laboratory equipment crucial for clinical, chemical, forensic, research, and industrial testing. Their offerings include the production of pipette tips, deep-well plates, microtubes, and PCR products, alongside assembly and post-processing services. They also specialize in primary pharmaceutical packaging solutions for solids, creams, and ophthalmic products, offering customized production to meet specific client needs. For the electronics and industrial sectors, Nolato excels in designing, developing, and manufacturing advanced components, sub-systems, and ready-to-market electronic goods. Examples of their contributions range from laser applications and ceramics to consumer devices like fitness trackers, loudspeaker systems, thermostats, webcams, and vaporizer heating products. Their portfolio also encompasses automotive components, EMI shielding, thermal interface materials, and silicone-based sealing and damping solutions. Additionally, Nolato supplies plastic parts and assembled units for food processing equipment, such as coffee machines and blenders. Established in 1938 as Nordiska Latexfabriken i Torekov AB, the company was rebranded as Nolato AB (publ) in 1982. Its headquarters remain in Torekov, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||